La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Lulus Fashion Lounge a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Lulus Fashion Lounge..

Lulus Fashion Lounge (NASDAQ:LVLU) Azioni, Catena delle Opzioni

Lulus Fashion Lounge

Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.

Lulu's Fashion Lounge Holdings, Inc. - Common Stock

Lulus Fashion Lounge Holdings Inc

Tilray Brands's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NYSE">TLRY</a>) short percent of float has risen 14.93% since its last report. The company recently reported that it has 162.14 million shares sold short, which is 17.47% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Tilray Brands Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742913926_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tilray Brands has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tilray Brands's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Tilray Brands's peer group average for short interest as a percentage of float is 12.75%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

TLRY

Is the Market Bullish or Bearish on Tilray Brands?

Citizens Financial Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>) short percent of float has risen 5.3% since its last report. The company recently reported that it has 9.90 million shares sold short, which is 2.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Citizens Financial Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742913921_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Citizens Financial Group has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Citizens Financial Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Citizens Financial Group's peer group average for short interest as a percentage of float is 3.87%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Citizens Financial Group's Recent Short Interest

SkyWest's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYW#NYSE">SKYW</a>) short percent of float has risen 24.9% since its last report. The company recently reported that it has 1.73 million shares sold short, which is 6.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.49 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>SkyWest Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742913916_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for SkyWest has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing SkyWest's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, SkyWest's peer group average for short interest as a percentage of float is 10.05%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SKYW

How Is The Market Feeling About SkyWest?

Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) has outperformed the market over the past 10 years by 2.99% on an annualized basis producing an average annual return of 13.79%. Currently, Equinix has a market capitalization of $83.25 billion. 
Buying $100 In EQIX: If an investor had bought $100 of EQIX stock 10 years ago, it would be worth $361.88 today based on a price of $855.30 for EQIX at the time of writing.
<h3>Equinix's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742913909_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

EQIX

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

ViaSat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) shares were trading relatively<a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener"> flat in the premarket session on Tuesday.</a>
The company today announced that the NATO Military Committee has approved its next-generation DARC-ssd 600 for securing up to NATO SECRET data at rest.
This approval and its listing in the NATO Information Assurance Product Catalogue confirm that Viasat&#8217;s solution meets NATO&#8217;s strict requirements for securing classified data from theft or compromise.
The DARC-ssd 600 provides enhanced protection for classified information across various systems, including laptops, tablets, desktops, and network-attached storage devices.
The new model, designed and manufactured in the U.K., features a 685 billion parameter architecture and uses hardware-based encryption for superior data security.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/guidance/25/03/44470278/shell-unveils-new-strategy-higher-buybacks-cost-cuts-and-10-annual-free-cash-flow-growth" rel="noreferrer noopener">Shell Unveils New Strategy: Higher Buybacks, Cost Cuts And 10% Annual Free Cash Flow Growth</a>
Viasat&#8217;s DARC-ssd 600 integrates 256-bit AES hardware encryption with full disk encryption, ensuring data is decrypted upon bootup and encrypted when powered off.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, VSAT stock has lost over 35% in the past month. Investors can gain exposure to the stock via&nbsp;Procure Space ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFO#NASDAQ">UFO</a>) and&nbsp;Invesco S&amp;P Smallcap 600 Pure Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RZV#NYSE">RZV</a>).
Recently, NASA selected Viasat to support its direct-to-Earth capabilities through the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/43106377/why-viasat-stock-is-gaining-today" rel="noreferrer noopener">Near Space Network Services contract.</a>
This is part of a five-year, multi-award indefinite delivery, indefinite quantity (IDIQ) contract, valued at $4.82 billion, with a potential five-year extension. Viasat is one of four commercial companies chosen for this initiative.
Under the contract, Viasat will provide global ground segment support services for NASA missions, initially focusing on low Earth orbit operations. Viasat will use its Real-Time Earth Ground-Segment-as-a-Service network to offer resilient, high-throughput satellite-to-ground communications.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/03/44471753/teslas-china-weekly-insured-numbers-hit-new-year-to-date-high-gary-black-says-tslas-europe-sales-decline-not-relevant" target="_blank" rel="noreferrer noopener">Tesla&#8217;s China Weekly Insured Numbers Hit New Year-To-Date High: Gary Black Says TSLA&#8217;s Europe Sales Decline Not Relevant</a></li>
</ul>
Photo: Shutterstock

Equities

Markets

Movers

General

Rydex ETF Trust S&P Smallcap 600 Pure Value ETF

VSAT

What's Going On With ViaSat Stock Today?

On Tuesday, EVgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) shares are trading higher after the company disclosed that the collaboration network with Pilot Company and General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) reached more than 130 electric vehicle (EV) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44471380/pilot-general-motors-and-evgo-connect-national-travel-corridors-with-ev-charging-infrastructure-in" rel="noreferrer noopener">fast-charging locations in over 25 states</a>.
The charging network offers an elevated experience along popular corridors and major interstates, enabling long-distance EV travel.
The company says that the charging stations are now accessible along major routes like I-75 from Michigan to Georgia, as well as regional corridors including Minneapolis to Milwaukee, Detroit to Cleveland, San Antonio to Houston, and Dallas to Nashville.
Notably, in 2022, all the companies disclosed their collaboration to establish up to 2,000 fast-charging stalls across 500 Pilot and Flying J locations.
EV drivers are expected to benefit from Pilot&#8217;s travel centers, which offer premium amenities typically unavailable at other charging sites, such as lounges, free Wi-Fi, on-site dining, grab-and-go food and beverages, and grocery and convenience items.
With EVgo's high-power chargers delivering up to 350 kW, drivers can recharge in as little as 15 minutes.
Dennis Kish, president of EVgo stated, &#8220;Infrastructure availability is a key factor for drivers considering the choice to drive electric, and EVgo will continue to deploy high-power charging infrastructure nationwide to support current and future EV drivers.
Wade Sheffer, vice president of GM Energy said, &#8220;With more than 130 locations now open, which customers can easily find using the GM brand app, we&#8217;re helping ensure that charging is seamless and convenient—so drivers can focus on the adventure ahead.&#8221;
Earlier this month, the company reported fourth-quarter loss per share of 11 cents, missed the analyst consensus estimate of 9 cents loss and sales of $67.51 million <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44112098/evgo-stock-slides-after-q4-eps-sales-miss-estimates" rel="noreferrer noopener">missed the street view of $69.1 million</a>.
Price Action: EVGO shares are up 1.75%at $2.8693 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/03/44290969/evgo-growth-dampened-by-doe-loan-and-ev-incentive-uncertainty-analyst-says" target="_blank" rel="noreferrer noopener">EVgo Growth Dampened By DOE Loan And EV Incentive Uncertainty, Analyst Says</a></li>
</ul>
Image courtesy of EVgo, Inc.

Contracts

Small Cap

EVGO

EVgo, Pilot, GM Reach Milestone With Over 130 Fast-Charging Stations For Long-Distance EV Travel

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Michael Halloran upgraded the rating for Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) from Neutral to Outperform and maintained the price target of $114. Pentair shares closed at $89.85 on Monday. <a href="https://www.benzinga.com/quote/PNR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst C. Gregory Peters upgraded HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) from Outperform to Strong Buy but lowered the price target from $120 to $115. HealthEquity shares closed at $90.32 on Monday. <a href="https://www.benzinga.com/quote/HQY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Kevin Yin upgraded MINISO Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) from Neutral to Overweight and raised the price target from $15 to $22. MINISO Group shares closed at $18.35 on Monday. <a href="https://www.benzinga.com/quote/MNSO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Madeline Brooks upgraded the rating for Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) from Underperform to Buy and raised the price target from $60 to $160. Cloudflare shares closed at $123.93 on Monday. <a href="https://www.benzinga.com/quote/NET/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Adam Jonas upgraded Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) from Equal-Weight to Overweight and boosted the price target from $260 to $280. Carvana shares closed at $213.63 on Monday.  <a href="https://www.benzinga.com/quote/CVNA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NET stock? Here&#8217;s what analysts think: 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44472214/wall-streets-most-accurate-analysts-spotlight-on-3-industrials-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Industrials Stocks Delivering High-Dividend Yields</a></li>
</ul>

Upgrades

Analyst Ratings

CVNA

MNSO

This Cloudflare Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Cassava Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) on Tuesday shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-<a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">moderate Alzheimer&#8217;s disease</a>.
REFOCUS-ALZ randomized approximately 1,125 people utilizing the same eligibility <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44471581/cassava-sciences-reports-topline-phase-3-refocus-alz-data" rel="noreferrer noopener">criteria as RETHINK-ALZ</a>.
Topline data indicate that REFOCUS-ALZ did not meet each of the prespecified co-primary, secondary and exploratory biomarker endpoints.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42164927/cassava-sciences-controversial-alzheimers-drug-fails-to-hit-primary-goal-in-pivotal-study-halts-late-stage-studies" rel="noreferrer noopener">Cassava Sciences Alzheimer&#8217;s Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies</a>
The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 76, assessed by the ADAS-COG12 and ADCS-ADL scales, comparing simufilam to placebo.
On ADAS-COG12 (cognitive scale, where lower numbers mean less cognitive impairment), scores rose by 4.97 and 5.26 points in the two simufilam cohorts and by 4.70 points in the placebo group.
Similarly, on ADCS-ADL (daily living where a higher number represents less functional impairment), scores fell by 6.27 and 6.43 points on simufilam arms and by 5.32 points on placebo.&nbsp;
REFOCUS-ALZ was discontinued in November following the report that a prior 52-week Phase 3 study, RETHINK-ALZ, did not meet its co-primary endpoints.
A large portion of subjects enrolled in REFOCUS-ALZ completed their final study visit prior to the termination of the trial. Simufilam continued to demonstrate an overall favorable safety profile.
&#8220;We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer&#8217;s disease. These results were unambiguous,&#8221; said Cassava Chief Executive Rick Barry.
&#8220;Cassava will discontinue all efforts to develop simufilam for Alzheimer&#8217;s disease and we expect to phase out the program by the end of Q2 2025,&#8221; Barry continued.
In February,&nbsp;Cassava Sciences entered into an agreement with Yale University for a license to intellectual property rights, including an exclusive license to an issued US method of treatment patent for simufilam as a potential treatment for seizures related to rare neurodevelopmental disorders, including <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44002323/cassava-sciences-licenses-simufilam-method-of-treatment-patent" rel="noreferrer noopener">tuberous sclerosis complex</a>.
Price Action: SAVA stock is down 22.1% at $2.18 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44463008/jp-morgan-sees-convincing-multi-billion-dollar-opportunity-for-alnylam-pharmaceuticals-upgrades-stock" target="_blank" rel="noreferrer noopener">Alnylam Pharmaceuticals Presents &#8216;Convincing Multi-Billion Dollar Opportunity&#8217;: Analyst Upgrades Stock</a></li>
</ul>
Image via Shutterstock

Biotech

Health Care

SAVA

Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop

<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/25084159/Solar-Space.jpeg" alt="" class="wp-image-8786" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/25084159/Solar-Space.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/25084159/Solar-Space-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/25084159/Solar-Space-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The leading solar cell maker is looking for capital support from a Hong Kong listing to tide it over while it waits for recovery in its oversupplied sector
Key Takeaways:
<ul>
<li>Solar Space has filed for a Hong Kong IPO, reporting it swung from a profit in 2023 to a 1.29 billion yuan loss last year</li>
<li>The entire solar sector is suffering from oversupply, but saw hints of stabilization as PV module prices ticked up in February for the first time in 30 months</li>
</ul>
While Chinese companies have dominated the global market for photovoltaic (PV) products, the fiercely competitive group has created its own overheated space by building up too much capacity, causing prices to plunge. That's sent most companies into the red, forcing them to rely on their own cash reserves or raise new money until the air clears.
One of the last non-listed majors,&nbsp;SolarSpace Technology Co. Ltd., is turning to the latter option, hoping investors will look past its sea of red ink to buy into its story of better times ahead for a leader that was the world's second-largest PV cell producer in 2024.
SolarSpace previously applied and was approved to list on Shenzhen's Nasdaq-style ChiNext Market in 2023. But it withdrew that application in June last year, after falling into the red in the year's first quarter amid strong sector headwinds and a weak domestic stock market. The company has pivoted to Hong Kong this year, boasting an A-list of domestic underwriters including Haitong Securities, China Securities International and Citic Securities.
Founded in 2011, SolarSpace is a leading manufacturer of solar cells that are at the core of each electricity-producing solar panel. It has broadened its scope in recent years to include PV modules as well. According to third-party market data in the&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107187/documents/sehk25031301468.pdf">listing application</a>&nbsp;filed earlier this month, SolarSpace ranked second among PV cell makers globally in 2024, with 14.6% of the market. Its primary buyers are major PV module makers, with nine out of the world's top 10 as its customers. The company now operates in more than 29 countries and regions and has more than 1,000 customers.
The PV cells that are SolarSpace's bread-and-butter are the most basic unit of photovoltaic panels, responsible for converting sunlight into electricity. Revenue from PV cells currently accounts for more than 80% of the company's total. Its newer PV module business is also growing steadily, with sales rising from 0.9GW in 2022 to 2.9GW in 2024, growing from 7.5% to 18.7% of its revenue over that period.
But like many of its peers up and down the solar equipment chain, the broader industry slump created by slowing demand and a massive addition of new capacity dragged SolarSpace into the red last year. As prices plunged, SolarSpace's revenue tumbled by 45.68% year-on-year to 11.32 billion yuan ($1.56 billion) last year. It recorded a loss of 1.29 billion yuan for the year – a stark contrast to its profit of 1.67 billion yuan in 2023.
<h4 class="wp-block-heading">Accumulating inventory</h4>
The average selling prices of PV cells, as well as the silicon wafers used to make them, have been sliding nonstop since the fourth quarter of 2023, driving down profitability for everyone. SolarSpace's application document shows that from 2022 to 2024, the overall average selling price of its PV cells dropped by roughly two-thirds from 0.99 yuan/W to just 0.32 yuan/W. In the process, its gross margin also plummeted from 11.8% in 2022 to a negative 10.1% last year.
As we've already noted, SolarSpace is hardly the only one suffering. Based on statistics cited by other media, 31 PV enterprises reported losses last year, accounting for more than 70% of the industry. Silicon wafer and battery module producers took the hardest hit, with big names like&nbsp;Eging Photovoltaic&nbsp;(600537.SH),&nbsp;TCL Zhonghuan&nbsp;(002129.SZ),&nbsp;Tongwei&nbsp;(600438.SH) and&nbsp;Drinda&nbsp;(002965.SZ) all now operating in the red.
Meanwhile, SolarSpace's debt-to-asset ratio, inventory and inventory turnover days are all deteriorating. Its debt-to-asset ratio rose from 79.1% in 2022 to 83.7% last year, while its inventory jumped 150% from 937 million yuan in 2022 to 2.4 billion yuan in 2024. As the market became flooded with solar cells, the company's inventory turnover days – the time needed to sell an average product – also more than tripled from 19.7 days in 2022 to 68 days last year. As its situation deteriorated, the company's cash fell from 1.92 billion yuan at the end of 2023 to 1.11 billion yuan at the end of last year.
Given its deteriorating situation, it's no wonder SolarSpace is desperate for an IPO. In such dire times, the company could have difficulty selling its story to investors, who are closely watching for when the situation might finally stabilize.
<h4 class="wp-block-heading">Glimmers of hope?</h4>
Such hope could be coming soon, following some positive signals since the start of the year. Part of that is coming from Beijing, which says new commercial and industrial distributed photovoltaic projects approved before the end of April can get big electricity subsidies. Moreover, all power generated by new distributed PV projects that launch after May 31 can enter the power market, using a bidding system with no more state subsidies.
These two looming dates have spurred a short-term boom in new projects and installations, helping to support PV battery and module prices. In February 2025, China's PV module prices rose 0.4%, marking their first increase in 30 months. The uptick, while quite small, has been enough to hearten industry players that the bottom of the current downturn could be near.
SolarSpace has also been active overseas in recent years, building presences in the U.S., Europe, the Middle East, Southeast Asia and South Asia. That's boosting its overseas revenue, which rose from 1.44 billion yuan in 2022, or 11.5% of its total, to 3.72 billion yuan last year, or 32.9%. The company said it plans to use funds from the listing to establish a new overseas production base in the U.S. state of North Carolina to produce high-efficiency photovoltaic cells.
While SolarSpace looks strong as a leading solar cell maker, its increasingly dire financial situation could still keep investors away if it makes it to the IPO finish line. At the end of the day, photovoltaic companies are still very much a group whose fate hinges on their industry's outlook. Accordingly, the latest state of the sector is likely to be the most important factor determining whether investors give SolarSpace a warm reception or the cold shoulder.

Asia

IPOs

China's Oversupplied Solar Sector Sees Hints Of Stabilization

BTIG analyst Gray Powell upgrades CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) from Neutral to Buy and announces $431 price target.

Price Target

CRWD

BTIG Upgrades CrowdStrike Holdings to Buy, Announces $431 Price Target

DA Davidson analyst Tom Forte maintains Lovesac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) with a Buy and maintains $35 price target.

LOVE

DA Davidson Maintains Buy on Lovesac, Maintains $35 Price Target

On Tuesday, Kezar Life Sciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) revealed topline results from the PORTOLA Phase 2a trial evaluating zetomipzomib for autoimmune hepatitis (AIH), a chronic liver disease where the body&#8217;s immune system attacks healthy liver cells, causing <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">inflammation and potential damage</a>.
Top-line data shows that zetomipzomib treatment resulted in higher rates of complete biochemical responses (CR) combined with the reduction of steroid dosage to 5 mg/day or less <a href="https://www.benzinga.com/pressreleases/25/03/b44470939/kezar-life-sciences-announces-positive-topline-results-from-the-portola-phase-2a-trial-evaluating-" target="_blank" rel="noreferrer noopener">compared to placebo</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41388135/penny-stock-kezar-life-sciences-rejects-acquisition-deal-from-concentra-biosciences-at-1-10share-" rel="noreferrer noopener">Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study</a>
In the ITT population:
<ul>
<li>Without regard to steroid taper (decrease slowly), 50.0% (8 of 16) of zetomipzomib patients achieved a CR, compared to 37.5% (3 of 8) of placebo patients.</li>
<li>31.3% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper to 5 mg/day or less, compared to 12.5% on placebo.</li>
<li>18.8% (3 of 16) of zetomipzomib patients achieved both a CR and complete steroid withdrawal to zero mg/day, compared to 0% on placebo patients.</li>
<li>The median duration of response in zetomipzomib patients achieving a CR was 27.6 weeks and no disease flares were reported in any zetomipzomib-treated patient achieving CR.</li>
</ul>
In the pre-specified subgroup analysis, 21 of the 24 patients entered the study on a steroid-based therapy at the time of screening:
<ul>
<li>Without regard to steroid taper, 57.1% (8 of 14) of zetomipzomib patients achieved a CR compared to 28.6% (2 of 7) of placebo patients.</li>
<li>35.7% (5 of 14) of patients on the zetomipzomib arm achieved a CR and steroid taper to 5 mg/day or less, compared to 0% (0 of 7) of placebo patients.</li>
<li>21.4% (3 of 14) of patients on the zetomipzomib arm achieved a CR and complete steroid withdrawal to zero mg/day, compared to 0% (0 of 7) of placebo patients.</li>
</ul>
Treatment-emergent adverse events were seen in all patients, with injection site reactions being the most commonly reported TEAE in both arms.
Price Action: KZR stock was down 9.09% at $5.60 during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44473331/core-mains-q4-earnings-falls-short-on-expectation-hits-sales-to-17-billion-announces-leadership-shake-up" target="_blank" rel="noreferrer noopener">Core &amp; Main Misses Q4 Earnings Estimates, Changes Leadership As Sales Reach $1.7 Billion</a></li>
</ul>
Photo: Shutterstock

Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate

Cryptocurrency analyst Benjamin Cowen has identified Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) approach to the bull market support band as a key inflection point that could decide its trend <a href="https://www.benzinga.com/money/bitcoin-price-prediction">for the coming months</a>.
What Happened: In a <a href="https://www.youtube.com/watch?v=Va4uxOptS4c">podcast</a> published on Monday, Cowen explained that this support zone, currently ranging between $88,400 and $95,000, aligns with the 21-week exponential moving average and 20-week simple moving average—technical levels that historically dictate Bitcoin's momentum. 
He noted that Bitcoin's 30% correction is still within normal bull market parameters.
Bitcoin often bounces back to this support band after corrections, similar to previous cycles. 
However, initial rejections at this level are common, with BTC attempting a breakout later—as seen in 2019 and 2023. "Sometimes, on the first approach, there can be a rejection before another attempt," he warned.
Comparing Bitcoin&#8217;s current correction to historical patterns, Cowen noted it remains within normal parameters for bull markets. "30% is still a reasonable correction. We had plenty of those even in 2017," he explained, adding that the drop in early 2017 that tested the previous yearly high was approximately 35%.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44454730/bitcoin-could-replace-tesla-in-magnificent-7-to-boost-returns-reduce-volatility-standard-chartered">Bitcoin Could Replace Tesla In &#8216;Magnificent 7&#8217; To Boost Returns, Reduce Volatility: Standard Chartered</a>
What's Next: For the broader market outlook, Cowen identified early to mid-April as the next potential period of concern when new macroeconomic data is released.
While acknowledging President Trump has "slowed down the rhetoric" <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44460515/how-white-houses-april-2-tariffs-might-jolt-bitcoin-traders">on April 2 tariffs</a>, he suggested these upcoming economic reports could influence whether Bitcoin successfully breaks through the bull market support band or experiences another rejection.
Regarding altcoins, Cowen maintained his view that "Bitcoin should still outperform most of the rest of the market," providing "exposure to the upside" while minimizing downside risk. 
He predicted Bitcoin dominance would "continue to slowly trend higher" as Bitcoin potentially uses "liquidity from the altcoin market to hopefully sustain itself for longer."
Read Next:
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44422785/prominent-bitcoin-trader-closes-longs-anticipates-pullback-to-83500">Prominent Bitcoin Trader Closes Longs, Anticipates Pullback To $83,500</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Tests Key Bull Market Support At $88,000: What Does Technical Analysis Say?

DA Davidson analyst Linda Bolton Weiser maintains Interparfums (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPAR#NASDAQ">IPAR</a>) with a Buy and maintains $170 price target.

IPAR

DA Davidson Maintains Buy on Interparfums, Maintains $170 Price Target

Stephens &amp; Co. analyst Terry McEvoy reiterates Associated Banc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASB#NYSE">ASB</a>) with a Equal-Weight and maintains $28 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Associated Banc, Maintains $28 Price Target

Morgan Stanley analyst Bob Huang maintains TWFG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWFG#NASDAQ">TWFG</a>) with a Equal-Weight and lowers the price target from $31 to $30.

TWFG

Morgan Stanley Maintains Equal-Weight on TWFG, Lowers Price Target to $30

The Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) today announced that it has filed its answer and counterclaims to the complaint brought by Albertsons in the Delaware Court of Chancery, in connection with the previous merger agreement between the two companies, which was terminated in December 2024.
As detailed in the court filing, while Kroger was working diligently to seek regulatory approval and close the merger, Albertsons was engaging in a secret and misguided campaign, together with C&amp;S Wholesale Grocers, the divestiture buyer, to pursue its own regulatory strategy, which ultimately undermined Kroger's efforts. Albertsons's misconduct shockingly came to light in the middle of the antitrust trials under government cross examination of Susan Morris, Albertsons's recently promoted CEO designate. As a result of its misconduct, Albertsons is not entitled to the $600 million termination fee under the terms of the parties' merger agreement, nor is Albertsons entitled to the other damages it seeks.
Kroger continues to capitalize on its business model, generating differentiated value for all stakeholders. This includes significant investments that are delivering lower prices and increasing wages, while further improving the experience for an expanding customer base. The Company recently reported quarterly results ahead of expectations and positive momentum in 2025, as it drives sustainable future growth and compelling total shareholder returns.

Guidance

Legal

Kroger Files Counterclaims Against Albertsons Over Terminated Merger, Seeks $600M Termination Fee Denial; Says Albertsons Misconduct Revealed During Antitrust Trials; Kroger Anticipates Growth In 2025

Stephens &amp; Co. analyst Mason Carrico downgrades Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) from Overweight to Equal-Weight and lowers the price target from $3.5 to $1.8.

Downgrades

AKYA

Stephens & Co. Downgrades Akoya Biosciences to Equal-Weight, Lowers Price Target to $1.8

WIIM

AVTX

Avalo Therapeutics shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating and announced a $23 price target. Also, Stifel initiated coverage on the stock with a Buy rating and announced a $36 price target.

On Tuesday, Chinese AI startup DeepSeek released its upgraded DeepSeek-V3-0324 model, <a target="_blank" href="https://www.benzinga.com/content/43851567/deepseeks-r1-model-revolutionizes-ai-landscape-says-expert-franklin-burgess" rel="noreferrer noopener">enhancing reasoning and coding abilities</a>.
Available on Hugging Face, the <a target="_blank" href="https://huggingface.co/deepseek-ai/DeepSeek-V3-0324" rel="noreferrer noopener">model</a> shows improved performance in technical benchmarks, intensifying competition with U.S. leaders like OpenAI and Anthropic.
The updated model has shown improvements across multiple benchmarks, particularly scoring 59.4 on the American Invitational Mathematics Examination, up from 39.6 in its predecessor, according to a <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3303798/deepseeks-upgraded-foundational-model-excels-coding-and-maths?firstTimeRegister=true" rel="noreferrer noopener">report </a>by the South China Morning Post.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44469333/alibabas-tsai-sounds-alarm-on-signs-of-ai-bubble-people-are-building-data-centers-on-speculation" rel="noreferrer noopener">Alibaba&#8217;s Tsai Sounds Alarm On Signs Of AI Bubble In US: &#8216;People Are Building Data Centers On Speculation&#8217;</a>
It also gained 10 points on LiveCodeBench, reaching a score of 49.2. The new model, with 685 billion parameters, uses an MIT software license, unlike DeepSeek V3, which has 671 billion parameters and a commercial license.
Earlier this year, DeepSeek&#8217;s R1 model disrupted American tech supremacy, sparking debates about Big Tech&#8217;s significant investments in large <a target="_blank" href="https://www.benzinga.com/content/43851567/deepseeks-r1-model-revolutionizes-ai-landscape-says-expert-franklin-burgess" rel="noreferrer noopener">language models and data centers.</a>
R1 made waves with its performance and lower costs, but analysts reportedly believe DeepSeek&#8217;s biggest impact is encouraging the use of open-source AI models, CNBC <a target="_blank" href="https://www.cnbc.com/2025/03/24/china-open-source-deepseek-ai-spurs-innovation-and-adoption.html" rel="noreferrer noopener">reports</a>. This shift has been a key factor in the company&#8217;s influence on the industry.
Wei Sun, principal analyst at Counterpoint Research, told CNBC that DeepSeek&#8217;s success shows open-source strategies drive faster innovation and wider adoption, with many companies adopting the model. She also mentioned that R1 is influencing China&#8217;s AI scene, prompting major firms like Baidu to open-source their own LLMs in response.
Recently, Kai-Fu Lee, the former head of Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)&nbsp;Google China and founder of AI startup&nbsp;01.AI, said that the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/02/37179799/elon-musk-taunts-sam-altman-and-openai-over-open-image" rel="noreferrer noopener">rise of open-source AI</a> models like&nbsp;DeepSeek&nbsp;has exposed an existential risk to OpenAI&#8217;s business—and he&#8217;s pivoting his company accordingly.
He questioned the long-term sustainability of OpenAI&#8217;s business model, especially when competing against open-source projects that offer similar quality at a fraction of the cost.
Tim Wang, managing partner at Monolith Management, shared in an <a target="_blank" href="https://www.cnbc.com/2025/03/24/china-open-source-deepseek-ai-spurs-innovation-and-adoption.html" rel="noreferrer noopener">interview</a> with CNBC that models from companies like DeepSeek have been powerful enablers in China, showing how progress can be made with fewer resources.
He noted that open-source models have reduced costs, allowing for product innovation—an area where Chinese companies excel.
Wang compared this development to the &#8220;Android moment,&#8221; when Google&#8217;s decision to make its operating system&#8217;s source code available sparked innovation in the app ecosystem.
He added that the perception of China being 12 to 24 months behind the U.S. in AI has now shifted to just 3 to 6 months.
This shift in China&#8217;s AI landscape, driven by open-source models like DeepSeek, is changing global competition and challenging traditional business models.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44465542/ai-investments-set-to-power-chip-revenue-boom-adoption-rises-among-large-companies-goldman-sachs" target="_blank" rel="noreferrer noopener">Goldman Sachs Predicts $305 Billion AI Windfall While Adoption Remains Slow</a></li>
</ul>
Image via Shutterstock

Tech

AMZN

GOOG

GOOGL

MSFT

TSLA

China's DeepSeek Ups The Heat In OpenAI Rivalry, Upgrades V3 Model Improving Coding And Reasoning Capability

Press Releases

Lulus Unveils New Strategic Initiative with D'Amelio Footwear

Lulus Releases Preliminary Second Quarter Results and Announces Second Quarter Earnings Call Date

Earnings

Lulus Reports Second Quarter 2024 Results

Management

Lulus Announces Reduction in Size of its Board of Directors

Lulus Joins Forces With Dillard's in Strategic U.S. Wholesale Expansion

Lulus to Report Third Quarter 2024 Results on November 13, 2024

Lulus Reports Third Quarter 2024 Results

Lulus Expands Strategic Wholesale Collaborations to Reach Customers in New Ways and Expand Market Presence

Lulus to Report Fourth Quarter and Full Year 2024 Results on March 27, 2025

Lulus Unveils New Brand Campaign to Expand Market Presence and Deepen Customer Loyalty

LVLU

a.k.a. Brands Holding

Birks Group

Cato Corporation (The) Class A Common Stock

Cato

Citi Trends

Designer Brands Inc. Class A Common Stock

Designer Brands

Duluth Holdings Inc. - Class B Common Stock

Duluth Holdings

Destination XL Group, Inc. - Common Stock

Destination XL Group

LightInTheBox Holding Co., Ltd. American Depositary Shares, each representing twelve ordinary shares

Comments

Lulus Fashion Lounge

Lulus Fashion Lounge (LVLU) Opzioni

Lulus Fashion Lounge (NASDAQ:LVLU) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO